Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/147438 |
Resumo: | Funding Information: Funding: This research was funded by Fundação para a Ciência e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/2014 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health—UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Fundação para a Ciência e Tecnolo-gia/Ministério da Ciência, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit—UCIBIO, which is financed by national funds from Fundação para a Ciência e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Funding Information: This research was funded by Funda??o para a Ci?ncia e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/20141 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health?UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Funda??o para a Ci?ncia e Tecnologia/Minist?rio da Ci?ncia, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit?UCIBIO, which is financed by national funds from Funda??o para a Ci?ncia e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. |
id |
RCAP_4a1eb03561d7bd2f87e439220fac5e96 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/147438 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancerAngiogenesisCell proliferationDLL1ER breast cancerMonoclonal antibodyNotch signalingTumor growthOncologyCancer ResearchSDG 3 - Good Health and Well-beingFunding Information: Funding: This research was funded by Fundação para a Ciência e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/2014 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health—UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Fundação para a Ciência e Tecnolo-gia/Ministério da Ciência, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit—UCIBIO, which is financed by national funds from Fundação para a Ciência e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Funding Information: This research was funded by Funda??o para a Ci?ncia e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/20141 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health?UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Funda??o para a Ci?ncia e Tecnologia/Minist?rio da Ci?ncia, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit?UCIBIO, which is financed by national funds from Funda??o para a Ci?ncia e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.The Notch-signaling ligand DLL1 has emerged as an important player and promising therapeutic target in breast cancer (BC). DLL1-induced Notch activation promotes tumor cell proliferation, survival, migration, angiogenesis and BC stem cell maintenance. In BC, DLL1 overexpression is associated with poor prognosis, particularly in estrogen receptor-positive (ER+) subtypes. Directed therapy in early and advanced BC has dramatically changed the natural course of ER+ BC; however, relapse is a major clinical issue, and new therapeutic strategies are needed. Here, we report the development and characterization of a novel monoclonal antibody specific to DLL1. Using phage display technology, we selected an anti-DLL1 antibody fragment, which was converted into a full human IgG1 (Dl1.72). The Dl1.72 antibody exhibited DLL1 specificity and affinity in the low nanomolar range and significantly impaired DLL1-Notch signaling and expression of Notch target genes in ER+ BC cells. Functionally, in vitro treatment with Dl1.72 reduced MCF-7 cell proliferation, migration, mammosphere formation and endothelial tube formation. In vivo, Dl1.72 significantly inhibited tumor growth, reducing both tumor cell proliferation and liver metastases in a xenograft mouse model, without apparent toxicity. These findings suggest that anti-DLL1 Dl1.72 could be an attractive agent against ER+ BC, warranting further preclinical investigation.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)iNOVA4Health - pólo NMSInstituto de Tecnologia Química e Biológica António Xavier (ITQB)DCV - Departamento de Ciências da VidaUCIBIO - Applied Molecular Biosciences UnitRUNSilva, GabrielaSales-Dias, JoanaCasal, Diogo B.Alves, SaraDomenici, GiacomoBarreto, ClaraMatos, CarolinaLemos, Ana R.Matias, Ana T.Kucheryava, KhrystynaFerreira, AndreiaMoita, Maria RaquelBraga, SofiaBrito, CatarinaCabral, M. GuadalupeCasalou, CristinaBarral, Duarte C.Sousa, Pedro M. F.Videira, Paula A.Bandeiras, Tiago M.Barbas, Ana2023-01-12T22:16:47Z2021-08-022021-08-02T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/147438eng2072-6694PURE: 33310345https://doi.org/10.3390/cancers13164074info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T18:08:04Zoai:run.unl.pt:10362/147438Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T18:08:04Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer |
title |
Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer |
spellingShingle |
Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer Silva, Gabriela Angiogenesis Cell proliferation DLL1 ER breast cancer Monoclonal antibody Notch signaling Tumor growth Oncology Cancer Research SDG 3 - Good Health and Well-being |
title_short |
Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer |
title_full |
Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer |
title_fullStr |
Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer |
title_full_unstemmed |
Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer |
title_sort |
Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer |
author |
Silva, Gabriela |
author_facet |
Silva, Gabriela Sales-Dias, Joana Casal, Diogo B. Alves, Sara Domenici, Giacomo Barreto, Clara Matos, Carolina Lemos, Ana R. Matias, Ana T. Kucheryava, Khrystyna Ferreira, Andreia Moita, Maria Raquel Braga, Sofia Brito, Catarina Cabral, M. Guadalupe Casalou, Cristina Barral, Duarte C. Sousa, Pedro M. F. Videira, Paula A. Bandeiras, Tiago M. Barbas, Ana |
author_role |
author |
author2 |
Sales-Dias, Joana Casal, Diogo B. Alves, Sara Domenici, Giacomo Barreto, Clara Matos, Carolina Lemos, Ana R. Matias, Ana T. Kucheryava, Khrystyna Ferreira, Andreia Moita, Maria Raquel Braga, Sofia Brito, Catarina Cabral, M. Guadalupe Casalou, Cristina Barral, Duarte C. Sousa, Pedro M. F. Videira, Paula A. Bandeiras, Tiago M. Barbas, Ana |
author2_role |
author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Centro de Estudos de Doenças Crónicas (CEDOC) iNOVA4Health - pólo NMS Instituto de Tecnologia Química e Biológica António Xavier (ITQB) DCV - Departamento de Ciências da Vida UCIBIO - Applied Molecular Biosciences Unit RUN |
dc.contributor.author.fl_str_mv |
Silva, Gabriela Sales-Dias, Joana Casal, Diogo B. Alves, Sara Domenici, Giacomo Barreto, Clara Matos, Carolina Lemos, Ana R. Matias, Ana T. Kucheryava, Khrystyna Ferreira, Andreia Moita, Maria Raquel Braga, Sofia Brito, Catarina Cabral, M. Guadalupe Casalou, Cristina Barral, Duarte C. Sousa, Pedro M. F. Videira, Paula A. Bandeiras, Tiago M. Barbas, Ana |
dc.subject.por.fl_str_mv |
Angiogenesis Cell proliferation DLL1 ER breast cancer Monoclonal antibody Notch signaling Tumor growth Oncology Cancer Research SDG 3 - Good Health and Well-being |
topic |
Angiogenesis Cell proliferation DLL1 ER breast cancer Monoclonal antibody Notch signaling Tumor growth Oncology Cancer Research SDG 3 - Good Health and Well-being |
description |
Funding Information: Funding: This research was funded by Fundação para a Ciência e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/2014 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health—UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Fundação para a Ciência e Tecnolo-gia/Ministério da Ciência, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit—UCIBIO, which is financed by national funds from Fundação para a Ciência e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Funding Information: This research was funded by Funda??o para a Ci?ncia e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/20141 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health?UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Funda??o para a Ci?ncia e Tecnologia/Minist?rio da Ci?ncia, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit?UCIBIO, which is financed by national funds from Funda??o para a Ci?ncia e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-08-02 2021-08-02T00:00:00Z 2023-01-12T22:16:47Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/147438 |
url |
http://hdl.handle.net/10362/147438 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2072-6694 PURE: 33310345 https://doi.org/10.3390/cancers13164074 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
_version_ |
1817545908065140736 |